WASHINGTON - Elusys Therapeutics Inc. won a five-year contract potentially worth $143 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance the development of the company's inhalational anthrax antitoxin Anthim, a high-affinity deimmunized monoclonal antibody. (BioWorld Today) Read More
